ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis

Endocrine therapy represents the cornerstone of treatment in hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). The natural course of this disease is marked by endocrine resistance, mainly due to Estrogen Receptor 1 (ESR1) acquired mutations. The aim of this study is to e...

Full description

Bibliographic Details
Main Authors: Loredana Urso, Grazia Vernaci, Jessica Carlet, Marcello Lo Mele, Matteo Fassan, Elisabetta Zulato, Giovanni Faggioni, Alice Menichetti, Elisabetta Di Liso, Gaia Griguolo, Cristina Falci, Pierfranco Conte, Stefano Indraccolo, Valentina Guarneri, Maria Vittoria Dieci
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
Estrogen Receptor 1 (ESR1)
metastatic breast cancer
endocrine therapy
ctDNA
liquid biopsy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.625636/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.625636/full

Similar Items